Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT

被引：0
|
作者：
Urbanska, E. [1 ]
Melchior, L. [2 ]
De Stricker, K. [2 ]
Sorensen, J. B. [1 ]
Rugiu, E. Santoni [2 ]
机构：
[1] Univ Copenhagen, Rigshosp, Dept Oncol, Finsens Ctr, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Pathol, Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK-positive NSCLC; resistance mechanisms; EMT;
D O I：
10.1016/j.jtho.2018.08.1769
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.08-18
引用
收藏
页码：S946 / S946
页数：1
相关论文
共 12 条
  • [1] Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
    Urbanska, Edyta M.
    Sorensen, Jens B.
    Melchior, Linea C.
    Costa, Junia C.
    Santoni-Rugiu, Eric
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (08)
  • [2] Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC
    Lu, S.
    Yu, Y.
    Ding, Y.
    Wu, X.
    Bao, H.
    Shao, Y. W.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S450 - S450
  • [3] Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
    Sanchez-Herrero, Estela
    Blanco Clemente, Mariola
    Calvo, Virginia
    Provencio, Mariano
    Romero, Atocha
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 366 - 372
  • [4] Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report
    He, Qiong
    Yu, Xinmin
    Yan, Junrong
    Shi, Xun
    Pan, Hongming
    HELIYON, 2024, 10 (11)
  • [5] Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs
    Wu, Lige
    Zou, Zihua
    Li, Yan
    Hao, Xuezhi
    Ying, Jianming
    Li, Junling
    Xing, Puyuan
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [6] Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment
    Bordi, Paola
    Tiseo, Marcello
    Rofi, Eleonora
    Petrini, Iacopo
    Restante, Giuliana
    Danesi, Romano
    Del Re, Marzia
    CLINICAL LUNG CANCER, 2017, 18 (06) : 692 - 697
  • [7] Next-Generation Sequencing Shows Mechanisms of Intrinsic Resistance in ALK-Positive NSCLC Patients Treated with Crizotinib
    Solomon, B.
    Soria, J.
    Blackhall, F.
    Shaw, A.
    Camidge, D. R.
    Kim, D.
    Mok, T.
    Fernandez-Banet, J.
    Kan, Z.
    Li, S.
    Liu, Y.
    Ho, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1898 - S1899
  • [8] Pathological complete remission in ALK-positive lung cancer patient after multiple lines of conversion therapy
    Que, Dan
    Zou, Hongbo
    Mao, Bijing
    Zhang, Huan
    Liang, Wei
    Liu, Qin
    Ke, Leiyu
    Guo, Lijie
    Xie, Qichao
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Non-Invasive Detection of Secondary Resistance Mutations in ALK-Positive NSCLC Patients by Next-Generation Sequencing
    Sanchez Herrero, E.
    Barquin, M.
    Calvo De Juan, V.
    Auglyte, M.
    Garcia Campelo, R.
    Sanchez, J. M.
    Domine, M.
    Massuti, B.
    Jantus, E.
    Camps, C.
    Reguart, N.
    Provencio, M.
    Romero, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S423 - S423
  • [10] Molecular Profile of Resistance Mutations Post Multiple Lines of Tyrosine Kinase Inhibitors in ALK-Positive Non-Small-Cell Lung Cancer
    Suryavanshi, M.
    Mattoo, S.
    Dhandha, S.
    Batra, U.
    Mehta, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1084 - S1085
12